Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer by 諛뺤듅�슦 et al.
1SCIentIfIC REPORtS |  (2018) 8:3383  | DOI:10.1038/s41598-018-21823-x
www.nature.com/scientificreports
Combined use of CEMIP and CA 
19-9 enhances diagnostic accuracy 
for pancreatic cancer
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Carbohydrate antigen (CA) 19-9 is the only diagnostic marker used in pancreatic cancer despite its 
limitations. Here, we aimed to identify the diagnostic role of CEMIP (also called KIAA1199) combined 
with CA 19-9 in patients with pancreatic cancer. A retrospective analysis of prospectively collected 
patient samples was performed to determine the benefit of diagnostic markers in the diagnosis of 
pancreatic cancer. We investigated CEMIP and CA 19-9 levels in 324 patients with pancreatic cancer and 
49 normal controls using serum enzyme-linked immunosorbent assay. Median CA 19-9 and CEMIP levels 
were 410.5 U/ml (40.8–3342.5) and 0.67 ng/ml (0.40–1.08), respectively, in patients with pancreatic 
cancer. The AUROC for CA 19-9 and CEMIP were 0.847 (95% confidence interval [CI]: 0.806–0.888) 
and 0.760 (95% CI: 0.689–0.831), respectively. Combination of CA 19-9 with CEMIP showed markedly 
improved AUROC over CA 19-9 alone in pancreatic cancer diagnosis (0.94 vs. 0.89; P < 0.0001). CEMIP 
showed a diagnostic yield of 86.1% (68/79) in CA 19-9 negative pancreatic cancer. Combined use with 
CEMIP showed significantly improved diagnostic value compared with CA 19-9 alone in pancreatic 
cancer. Especially, CEMIP may be a complementary marker in pancreatic cancer patients with normal CA 
19-9 levels.
Pancreatic cancer is a highly malignant tumor with a poor prognosis. Most patients (80%) present with inop-
erable advanced pancreatic cancer at the time of initial diagnosis1. Although carbohydrate antigen (CA) 19-9 is 
known as a pancreatic cancer biomarker, it is not commonly used for general screening, owing to its low sensitiv-
ity and specificity2–4. In particular, false-negative results in the segment of the population with Lewis blood type 
A-B- and false-positive results in patients with obstructive jaundice limit the specificity of CA 19-9 for pancreatic 
cancer5,6. Therefore, development of novel diagnostic markers is required for the early detection of pancreatic 
cancer. Previous studies have suggested alternative biomarkers to compensate for the limitations of CA 19-9 in 
patients with pancreatic cancer7–9.
CEMIP was originally identified as a hearing loss-related gene. Increased expression of cell migration-inducing 
hyaluronan binding protein (CEMIP), a newly identified protein involved in hyaluronan degradation10, 
has been reported in various cancers. CEMIP contributes to breast cancer cell migration with induction of 
epithelial-mesenchymal transition via calcium signaling11,12. Additionally, CEMIP expression is associated with 
gastric and colorectal tumorigenesis and it is a potential biomarker of gastric cancer13–15.
Recently, several studies have investigated the role of CEMIP in pancreatic cancer; CEMIP has been reported 
to be associated with early detection, cancer cell migration, invasion, and poor prognosis in previous stud-
ies10,16,17. Suh et al. suggested that CEMIP may be useful for detecting pancreatic cancer at an early stage16, while 
Koga et al. demonstrated its association with prognosis in pancreatic cancer10. However, the sample sizes of these 
previous studies were too small to draw a solid conclusion10,16,17. On the other hand, despite its limitations, CA 
19-9 has been proposed as a diagnostic tool for the detection of pancreatic cancer. To date, there have been no 
studies investigating the diagnostic accuracy of serum CA 19-9 in combination with CEMIP for pancreatic can-
cer, as compared with serum CA19-9 alone.
1Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. 
2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. 3Biostatistics Collaboration Unit, 
Yonsei University College of Medicine, Seoul, Korea. Correspondence and requests for materials should be addressed 
to S.Y.S. (email: sysong@yuhs.ac)
Received: 7 November 2017
Accepted: 6 February 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIentIfIC REPORtS |  (2018) 8:3383  | DOI:10.1038/s41598-018-21823-x
Therefore, we aimed to investigate the differences in CEMIP expression in whole blood between patients with 
pancreatic cancer and healthy participants, and to identify the role of CEMIP compared with that of CA 19-9 in 
the diagnosis of pancreatic cancer.
Methods
Patients. We performed a retrospective analysis of prospectively collected patient samples including pan-
creatic cancer patients and normal individuals between 2007 and 2015. As a control group, normal individuals 
were defined as people who were not diagnosed with pancreatic cancer, and these individuals were divided into 
two groups: healthy individuals and patients with benign diseases. Blood samples were obtained immediately 
following diagnosis and prior to the administration of any oncological or surgical treatment. Information regard-
ing patient demographics and clinical data was obtained from the electronic medical records, including age at 
diagnosis, sex, location of cancer, serum levels of CA 19-9, antitumor treatment, and tumor stage. Tumor stages 
were based on the staging classification of the 7th edition of the American Joint Committee on Cancer (AJCC)18. 
Written informed consent was obtained from all patients who approved the use of their blood, and this study was 
approved by the institutional review board of Yonsei University.
CA 19-9 and CEMIP. All methods were performed in accordance with relevant guidelines and regulations. 
CA 19-9 was measured using chemiluminescence immunoassay on the VITROS 3600 Immunodiagnostic System 
(Ortho-Clinical Diagnostics Inc., Raritan, NJ, USA). The standard diagnostic cutoff value for CA 19-9 was 37 U/mL. 
The levels of CEMIP were measured using the enzyme-linked immunosorbent assay (ELISA) method. We 
detected secreted CEMIP protein in blood samples obtained from patients with pancreatic cancer and individuals 
without cancer. A 96-well CEMIP ELISA kit (SER965Hu) was purchased from USCN Life Science, Inc. (Wuhan, 
China) and the procedure was performed according to the manufacturer’s instructions. The detection range for 
the ELISA kit used was 0.156–10 ng/ml. The standard curve concentrations used for the ELISAs were 10, 5, 2.5, 
1.25, 0.625, 0.312, and 0.156 ng/ml. The sensitivity of this assay, or lower limit of detection (LLD), was defined as 
the lowest protein concentration that could be differentiated from zero. It was determined by adding two standard 
deviations to the mean optical density value of 20 standard replicates and calculating the corresponding concen-
tration. No significant cross-reactivity or interference between CEMIP and analogues was observed.
Statistical analyses. All statistical analyses were performed using SPSS for Windows version 20.0 (SPSS, 
Inc., Chicago, IL, USA), SAS (version 9.4, SAS Inc., Cary, NC, USA), and R package, version 3.0.1. For com-
parison of serum values between normal individuals and patients with pancreatic cancer, Student’s t test was 
employed. The receiver operating characteristic (ROC) curve and the area under the ROC curve (AUROC) were 
calculated to identify the optimal cut-off CEMIP level associated with diagnosis. We used MedCalc version 11.1 
for the ROC analysis (MedCalc Software, Mariakerke, Belgium). The bootstrapping method (1,000 replications) 
was applied for internal validation of the AUROC. We used Contal and O’Quigley’s method of categorizing 
patients into high or low risk groups for overall survival and chose a cut-off point of CEMIP according to the 
method19. Survival curves were estimated using the Kaplan-Meier method, and the differences among curves 
were assessed using log-rank tests. A P-value < 0.05 was considered to be statistically significant. Univariate and 
multivariate analysis was performed using Cox regression analysis for risk factors influencing survival in patients 
who were diagnosed with pancreatic cancer. GraphPad Prism 4 software (GraphPad Software, San Diego, CA, 
USA) was used for construction of graphs.
Results
Patient characteristics. Serum samples were obtained from 324 patients diagnosed with pancreatic can-
cer and 49 normal individuals at the Severance Hospital. Normal individuals were divided into two groups: 30 
healthy individuals and 19 patients with benign diseases such as common bile duct stone (n = 2), gallbladder 
stone (n = 4), intrahepatic stone (n = 1), cholecystitis (n = 4), liver abscess (n = 1), acute hepatitis (n = 1), acute 
pancreatitis (n = 1), duodenal polyp (n = 1), gastric ulcer (n = 1), and benign pancreatic cyst (n = 3). Table 1 
shows the baseline characteristic of patients in the present study. The median age of patients was 63 years (men, 
64.5%). About 75% of patients received palliative chemotherapy, and 170 patients (52%) were diagnosed with 
stage IV pancreatic cancer. The median overall survival was 314 days (169–581). The median levels of CA 19-9 
and CEMIP were 410.5 U/ml (40.8–3342.5) and 0.67 ng/ml (0.40–1.08), respectively, in patients with pancreatic 
cancer.
CEMIP as diagnostic marker. Using the Mann-Whitney U test, the CA 19-9 levels were found to be signifi-
cantly elevated in the serum of patients with pancreatic cancer compared with normal individuals (median, 410.5 
vs. 10.8 U/ml, P < 0.001). Moreover, CEMIP also exhibited significantly higher expression levels in patients with 
pancreatic cancer than in normal individuals (0.67 vs. 0.16 ng/ml, P < 0.001) (Fig. 1).
The ROC curve analysis indicated the potential diagnostic values of these markers (Fig. 2): The AUROCs for 
CA 19-9 and CEMIP were 0.85 (95% confidence interval [CI]: 0.806–0.888) and 0.76 (95% CI: 0.689–0.831), 
respectively. CEMIP also showed good diagnostic performance in internal validation (bootstrap-corrected 
AUROC, 0.76; 95% CI, 0.692–0.833). Combined ROC curve analysis using CA 19-9 and CEMIP revealed an 
AUROC of 0.89 (95% CI: 0.862–0.920) with a sensitivity of 80.3% and a specificity of 97.9% in discriminating 
pancreatic cancer patients from normal individuals. Combination of CA 19-9 with CEMIP showed markedly 
improved AUROC over that of CA 19-9 alone in the diagnosis of pancreatic cancer against normal individuals 
(AUROC, 0.89 vs. 0.85; P = 0.0119) (Fig. 2A). With combined CEMIP and CA 19-9, the test showed better sensi-
tivity and negative predictive value compared to CA 19-9 alone (Table 2).
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Additional subgroup analysis was performed by including only healthy individuals among all normal indi-
viduals. Combination of CA 19-9 with CEMIP showed markedly improved AUROC over that of CA 19-9 alone 
in the diagnosis of pancreatic cancer against healthy individuals (AUROC, 0.94 vs. 0.88; P < 0.0001) (Fig. 2B).
CEMIP in CA 19-9 negative patients. Among 324 patients who were diagnosed with pancreatic cancer, 79 
patients demonstrated CA 19-9 levels below 37 U/ml, and 19 patients were Lewis blood type A-B-. The proportion 
of patients who showed high CEMIP levels (≥0.218 ng/ml) among pancreatic cancer patients with CA 19-9 in the 
normal range (<37 U/ml) was 86.1% (Supplementary Table 1). Among 79 patients with CA 19-9 in the normal 
range, 68 patients (black colored circle) were diagnosed using CEMIP (diagnostic yield, 86.1%) (Fig. 3).
CEMIP as prognostic predictive marker. We selected the optimal cut-off value of CEMIP to maximize the 
survival difference using Contal and O’Quigley’s method (CEMIP = 0.429 ng/ml). Using Kaplan-Meier curves, we 
examined the correlation between CEMIP expression and survival in patients with pancreatic cancer. Survival analysis 
revealed a significantly shorter overall survival in the high CEMIP expression group (≥0.429 ng/ml) compared with the 
low CEMIP expression group (<0.429 ng/ml) (9.8 vs. 13.7 months, log-rank test P = 0.0175) (Fig. 4).
Variables Patients (n = 324)
Age 63.0 ± 10.6
Men 209 (64.5%)
Location
  Head 168 (51.9%)
  Body 66 (20.4%)
  Tail 58 (17.9%)
  Mixed 32 (9.8%)
Antitumor treatment
Operation
  Whipple procedure 4 (1.2%)
  PPPD 47 (14.5%)
  Total pancreatectomy 1 (0.3%)
  Distal pancreatectomy 13 (4.0%)
  Chemotherapy 245 (75.6%)
  Supportive care 14 (4.3%)
Stage
  I 4 (1.2%)
  II 89 (27.5%)
  III 61 (18.8%)
  IV 170 (52.5%)
  CEMIP, ng/mL 0.67 (0.40–1.08)
  CA 19–9, U/mL 410.5 (40.8–3342.5)
  Overall survival 314 days (169–581)
Table 1. Baseline characteristics. Variables are expressed as mean ± standard deviation, median (interquartile 
range), or n (%). PPPD, pylorus-preserving pancreaticoduodenectomy; CEMIP, cell migration-inducing 
hyaluronan binding protein; CA 19-9, carbohydrate antigen 19-9.
Figure 1. Summary of serum CEMIP expression levels detected from pancreatic cancer patients and 
individuals without cancer. The CEMIP expression was significantly higher in patients with pancreatic cancer 
than in individuals without cancer (P < 0.001 by paired t-test). The horizontal lines represent the median values. 
CEMIP, cell migration-inducing hyaluronan binding protein; PDAC, pancreatic ductal adenocarcinoma.
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To further determine the prognostic value of CEMIP expression for pancreatic cancer, clinicopathological 
variables as well as CEMIP expression status were analyzed using Cox proportional hazard models. Univariate 
analysis revealed significant prognostic factors including high CEMIP expression, age, anticancer treatment, and 
tumor stage (P < 0.05). Multivariate analysis revealed that high CEMIP expression (hazard ratio [HR], 1.646; 
95% CI, 1.224–2.214; P = 0.001) was a significant independent prognostic factor after adjustment for potential 
confounding factors (Table 3). In 2 patients whose CEMIP and CA 19-9 levels were serially checked two times 
with tumor response evaluation, CEMIP showed a predictive function for treatment response, and it accurately 
predicted cancer progression compared to CA 19-9 (Supplementary Figure 1).
Figure 2. ROC curves of CEMIP, CA 19-9, and both to diagnose pancreatic cancer. Normal individuals were 
defined as people who were not diagnosed with pancreatic cancer and were divided into two groups (healthy 
individuals and patients with benign disease). (A) Normal individuals including healthy individuals and 
patients with benign disease were the control group. Combination with CEMIP showed markedly improved 
AUROC over that of CA 19-9 alone in the diagnosis of pancreatic cancer against normal individuals 
(AUROC, 0.89 vs. 0.85; P = 0.0119). (B) Healthy individuals were the control group. Combination with 
CEMIP showed markedly improved AUROC over that of CA 19-9 alone in the diagnosis of pancreatic cancer 
against healthy individuals (AUROC, 0.94 vs. 0.89; P < 0.0001). CEMIP, cell migration-inducing hyaluronan 
binding protein; CA 19-9, carbohydrate antigen 19-9; ROC, receiver operating characteristic; AUC, area 
under the ROC curve.
Test Sensitivity (%) Specificity (%) PPV (%) NPV (%)
CA 19-9 75.6 93.8 98.7 36.8
CEMIP 92.9 59.2 93.7 55.7
CEMIP + CA 
19-9 96.6 59.2 94.0 72.5
Table 2. Performance characteristics of CA 19-9 and CEMIP. PPV, Positive predictive value; NPV, Negative 
predictive value; CA 19-9, Carbohydrate antigen 19-9.
Figure 3. Distribution of CEMIP and CA 19-9 levels in patients diagnosed with pancreatic cancer. The optimal 
cut-off levels of CA 19-9 and CEMIP were 37 U/mL and 0.218 ng/ml, respectively. A total of 68 CA 19-9 negative 
patients (black colored circle) were diagnosed using CEMIP (diagnostic yield, 86.1%). CEMIP, cell migration-
inducing hyaluronan binding protein; CA 19-9, carbohydrate antigen 19-9.
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Discussion
This study describes a novel biomarker, CEMIP, which may be used in combination with CA 19-9 in whole blood 
in the diagnosis of pancreatic cancer. CEMIP synergizes with CA 19-9 in its diagnostic function for pancreatic 
cancer. Combining CA 19-9 with CEMIP increased the AUROC compared with CA 19-9 alone in all groups. 
These results suggest the usefulness of CEMIP in combination with CA 19-9 or in situations in which the CA19-9 
level is normal.
Cancer stem cells (CSCs) are potential diagnostic and therapeutic targets because of their roles in carcino-
genesis20,21. In recent research, CSC-related biomarkers have been suggested as potential reliable biomarkers 
for tumor detection22,23. We previously performed cDNA microarrays using adherent and sphere cells from the 
human pancreatic cancer cell lines Capan-1 and HPAC to evaluate the unique molecular patterns of pancreatic 
CSCs24. We characterized biomarkers for distinguishing pancreatic CSCs from cancer cells. cDNA microarrays 
with sphere and adherent cells derived from Capan-1 and HPAC cell lines revealed that the CEMIP gene was 
Figure 4. Correlation between CEMIP and survival in patients with pancreatic cancer using Kaplan-Meier 
curve. Low CEMIP levels were significantly associated with longer overall survival (median overall survival, 
13.7 vs. 9.8 months, P = 0.0175). CEMIP, cell migration-inducing hyaluronan binding protein.
Variable
Univariate
Variable
Multivariate
HR (95% CI) P-value HR (95% CI) P-value
  CEMIP, mg/dL CEMIP, mg/dL
  <0.429 Ref. <0.429 Ref.
  ≥0.429 1.378 (1.056-1.798) 0.018 ≥0.429 1.646 (1.224–2.214) 0.001
  Age 1.022 (1.010–1.035) 0.001 Age 1.022 (1.009–1.036) 0.001
Sex
  Women Ref.
  Men 1.219 (0.957–1.552) 0.108
Diabetes mellitus
  No Ref.
  Yes 0.947 (0.729–1.229) 0.680
Treatment Treatment
  Supportive care Ref. No Ref.
  Chemotherapy 0.521 (0.280–0.970) 0.039 Yes 0.243 (0.128–0.462) <0.001
  Operation 0.134 (0.069–0.263) <0.001
Location of cancer
  Head Ref.
  Body 1.372 (1.013–1.859) 0.041
  Tail 1.444 (1.049–1.986) 0.024
  Mixed 1.344 (0.883–2.045) 0.167
Stage Stage
  I and II Ref. I and II Ref.
  III 1.228 (0.862–1.748) 0.254 III 1.733 (1.137–2.639) 0.011
  IV 3.754 (2.807–5.020) <0.001 IV 5.310 (3.663–7.696) <0.001
Table 3. Univariate and multivariate analysis for risk factors influencing survival in patients diagnosed with 
pancreatic cancer. A P-value < 0.02 was considered statistically significant. We found the cut-off point to 
maximize the survival curve using Contal and O’Quigley’s method. HR, hazard ratio; CI, confidence interval.
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upregulated in sphere cells, but not in adherent Capan-1 and HPAC cells (data not shown, Jang et al., submitted). 
Among the candidate genes identified in this work, we were particularly interested in the CEMIP gene, which has 
not been studied extensively in CSCs21,25,26. We focused on the role of CEMIP in relation to CSC-related func-
tions, especially diagnostic and prognostic function. CSC-related markers have been shown to aid early detection 
in cancer and have been associated with chemotherapy resistance and prognosis, because CSCs are known as 
tumor-initiating cells and conventional anticancer treatments do not target CSCs20–23,27–29.
Combining detection with different biomarkers has been reported to be a useful strategy in several studies, as 
it increases the sensitivity and specificity of each biomarker. In a combined ROC analysis using the two markers, 
both sensitivity and specificity reached a relatively high value in discriminating patients with pancreatic cancer 
from healthy individuals. Recent studies reported the effect of combined metabolic biomarkers or microRNA 
based molecular markers in pancreatic cancer diagnosis8,9. However, no reliable CSC-related biomarker has been 
established for pancreatic cancer diagnosis and prognosis combined with widely used CA 19-9. Our results sug-
gest that the combination of CA 19-9 and CEMIP serum assays may offer a useful tool for the detection of pan-
creatic cancer.
Regarding early-stage pancreatic cancer screening, endoscopic ultrasound, magnetic resonance imaging, and 
computed tomography have been used in previous studies for several decades as a first choice in patients with 
high risk factors30–37. However, those procedures are associated with low compliance in the clinical setting due 
to their invasive and expensive character. Therefore, cost-effective and non-invasive biomarkers with high sensi-
tivity and specificity are needed to enable early detection of early-stage pancreatic cancer. Thus, we evaluated the 
diagnostic performance of CEMIP in patients with stage I & II pancreatic cancer. In early-stage pancreatic cancer, 
combined use of CEMIP and CA 19-9 showed higher AUROC than CA 19-9 alone (0.95 vs. 0.85, P = 0.0004) 
(Supplementary Figure 2).
There are several strengths in the present study. First, this study is the largest to investigate the role of CEMIP 
in pancreatic cancer. Second, this study is based on the finding that CEMIP is associated with CSCs. No previ-
ous studies have investigated the association between CEMIP and CSCs or the role of CEMIP as a CSC-related 
marker. Third, all clinical data and blood samples were collected from a large-scale prospective cohort of patients 
with pancreatic cancer.
However, there are also several limitations in this study. First, owing to restrictions in the sampling of healthy 
participants, there was a significant difference in age (P < 0.001) between patients with pancreatic cancer and 
normal individuals (mean age, 63 vs. 49 years). Thus, the outcome might be confounded by age for healthy 
blood donors. However, separate analysis for cases and controls revealed no correlation between age and CEMIP 
(Supplementary Figure 3). This finding suggests that CEMIP might be a useful diagnostic biomarker independ-
ent of age. In addition, the number of individuals in the control groups is small compared to the number in the 
group with pancreatic cancer. Future prospective studies with large sample sizes including healthy individuals 
and patients with premalignant disease may further support our results. Lastly, the specificity of combination 
of CEMIP and CA19-9 was low (59.2%) even though the sensitivity was high (96.6%). Although the specificity 
of CEMIP was high (90.0%) to identify patients with pancreatic cancer when compared to the normal controls 
without benign diseases, it became low probably due to the high number of false-positive cases. Therefore, clini-
cians should be careful to use CEMIP and CA 19-9 as biomarkers for pancreatic cancer diagnosis in patients with 
benign disease. For these patients, other examinations including endoscopic ultrasonography and abdominal 
computed tomography scan might be helpful to complement the low specificity of the combination of CEMIP 
and CA 19-9.
In conclusion, serum ELISA analysis showed that CEMIP proteins were highly expressed in patients with 
pancreatic cancer compared to healthy individuals. Combined use of CA 19-9 and CEMIP significantly increased 
the sensitivity and specificity in discriminating not only patients with all stage pancreatic cancer but also patients 
with stage I/II pancreatic cancer from healthy individuals. Therefore, combined detection with serum CA 19-9 
and CEMIP levels may have the potential to become a new laboratory method for the clinical diagnosis of pan-
creatic cancer.
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